(PolyPreventHF) (NCT06143566) will investigate the effect of a combination of empagliflozin, losartan and finerenone in patients with T2DM and a high risk of HF [48], while (Steno1) (NCT06082063) will investigate the effect of a multifactorial intervention with among others semaglutide, sotagliflozin, finerenone, ezetimibe and/or PCSK9-inhibitors in patients with type 1 diabetes at high risk of cardiovascular diseases [49]. Here, PCSK9 is linked to type 2 diabetes mellitus.